Medical Radiology and Radiation Safety. 2024. Vol. 69. № 3

DOI:10.33266/1024-6177-2024-69-3-35-45

A.V. Rodina

The Mitochondrial 18 kDa Translocator Protein 
as a Biomarker of Radiation-Induced Neuroinflammatory

NRC Kurchatov Institute, Moscow, Russia

Contact person: A.V. Rodina, е-mail: Этот адрес электронной почты защищен от спам-ботов. У вас должен быть включен JavaScript для просмотра.

 

CONTENTS

The review presents current knowledge about the structure of the18 kDa translocator  protein TSPO, its polymorphic variants, regulation of its gene expression and function in the cells of CNS. Particular attention is paid to its role in mitochondrial homeostasis in microglia under neuroinflammation in the long-term period after ionizing radiation exposure. Data on the effectiveness of several TSPO ligands for diagnostic imaging and treatment of neuroinflammation for restoring cognitive functions in neurodegenerative pathologies are summarized. Based on the TSPO level in the brain and in the peripheral blood cells late after irradiation, TSPO is discussed as a potential marker of neuroinflammation development.

Keywords: ionizing radiation, radiation-induced neuroinflammation, microglia, translocator protein TSPO, positron emission tomography, radioligand

For citation: Rodina AV. The Mitochondrial 18 kDa Translocator Protein as a Biomarker of Radiation-Induced Neuroinflammatory. Medical Radiology and Radiation Safety. 2024;69(3):35–45. (In Russian). DOI:10.33266/1024-6177-2024-69-3-35-45

  

References

1. Betlazar C, Middleton RJ, Banati RB, Liu GJ. The Impact of High and Low Dose Ionising Radiation on the Central Nervous System. Redox Biol. 2016;9:144-56. doi: 10.1016/j.redox.2016.08.002.

2. Liu Q, Huang Y, Duan M, Yang Q, Ren B, Tang F. Microglia as Therapeutic Target for Radiation-Induced Brain Injury. International Journal of Molecular Sciences. 2022;23(15). doi: 10.3390/ijms23158286.

3. Maeda J, Higuchi M, Inaji M, Ji B, Haneda E, Okauchi T, et al. Phase-Dependent Roles of Reactive Microglia and Astrocytes in Nervous System Injury as Delineated by Imaging of Peripheral Benzodiazepine Receptor. Brain Research. 2007;1157:100-11. doi: 10.1016/j.brainres.2007.04.054.

4. Betlazar C, Middleton RJ, Banati R, Liu GJ. The Translocator Protein (TSPO) in Mitochondrial Bioenergetics and Immune Processes. Cells. 2020;9(2). doi: 10.3390/cells9020512.

5. Braestrup C, Squires RF. Specific Benzodiazepine Receptors in Rat Brain Characterized by High-Affinity (3h)Diazepam Binding. Proceedings of the National Academy of Sciences of the United States of America. 1977;74(9):3805-9. doi: 10.1073/pnas.74.9.3805.

6. Mukhin AG, Papadopoulos V, Costa E, Krueger KE. Mitochondrial Benzodiazepine Receptors Regulate Steroid Biosynthesis. Proceedings of the National Academy of Sciences of the United States of America. 1989;86(24):9813-6. doi: 10.1073/pnas.86.24.9813.

7. Sprengel R, Werner P, Seeburg PH, Mukhin AG, Santi MR, Grayson DR, et al. Molecular Cloning and Expression of CDNA Encoding a Peripheral-Type Benzodiazepine Receptor. The Journal of Biological Chemistry. 1989;264(34):20415-21. doi: 

8. Gatliff J, Campanella M. TSPO: Kaleidoscopic 18-Kda Amid Biochemical Pharmacology, Control and Targeting of Mitochondria. The Biochemical Journal. 2016;473(2):107-21. doi: 10.1042/bj20150899.

9. Li F, Liu J, Liu N, Kuhn LA, Garavito RM, Ferguson-Miller S. Translocator Protein 18 kDa (TSPO): an Old Protein with New Functions? Biochemistry. 2016;55(20):2821-31. doi: 10.1021/acs.biochem.6b00142.

10. Papadopoulos V, Fan J, Zirkin B. Translocator Protein (18 kDa): an Update on its Function in Steroidogenesis. Journal of Neuroendocrinology. 2018;30(2). doi: 10.1111/jne.12500.

11. Betlazar C, Harrison-Brown M, Middleton RJ, Banati R, Liu GJ. Cellular Sources and Regional Variations in the Expression of the Neuroinflammatory Marker Translocator Protein (TSPO) in the Normal Brain. International Journal of Molecular Sciences. 2018;19(9). doi: 10.3390/ijms19092707.

12. Notter T, Schalbetter SM, Clifton NE, Mattei D, Richetto J, Thomas K, et al. Neuronal Activity Increases Translocator Protein (TSPO) Levels. Molecular Psychiatry. 2021;26(6):2025-37. doi: 10.1038/s41380-020-0745-1.

13. Boyd A, Byrne S, Middleton RJ, Banati RB, Liu GJ. Control of Neuroinflammation through Radiation-Induced Microglial Changes. Cells. 2021;10(9). doi: 10.3390/cells10092381.

14. Milenkovic VM, Slim D, Bader S, Koch V, Heinl ES, Alvarez-Carbonell D, et al. CRISPR-Cas9 Mediated TSPO Gene Knockout alters Respiration and Cellular Metabolism in Human Primary Microglia Cells. International Journal of Molecular Sciences. 2019;20(13). doi: 10.3390/ijms20133359.

15. Loth MK, Guariglia SR, Re DB, Perez J, de Paiva VN, Dziedzic JL, et al. A Novel Interaction of Translocator Protein 18 kDa (TSPO) with NADPH Oxidase in Microglia. Mol Neurobiol. 2020;57(11):4467-87. doi: 10.1007/s12035-020-02042-w.

16. Lee Y, Park Y, Nam H, Lee JW, Yu SW. Translocator Protein (TSPO): the New Story of the Old Protein in Neuroinflammation. BMB Reports. 2020;53(1):20-7. doi: 10.5483/BMBRep.2020.53.1.273.

17. Liu GJ, Middleton RJ, Hatty CR, Kam WW, Chan R, Pham T, et al. The 18 kDa Translocator Protein, Microglia and Neuroinflammation. Brain Pathology (Zurich, Switzerland). 2014;24(6):631-53. doi: 10.1111/bpa.12196.

18. Owen DR, Yeo AJ, Gunn RN, Song K, Wadsworth G, Lewis A, et al. An 18-kDa Translocator Protein (TSPO) Polymorphism Explains Differences in Binding Affinity of the PET Radioligand PBR28. J Cereb Blood Flow Metab. 2012;32(1):1-5. doi: 10.1038/jcbfm.2011.147.

19. Werry EL, Bright FM, Piguet O, Ittner LM, Halliday GM, Hodges JR, et al. Recent Developments in TSPO PET Imaging as a Biomarker of Neuroinflammation in Neurodegenerative Disorders. International Journal of Molecular Sciences. 2019;20(13). doi: 10.3390/ijms20133161.

20. Zürcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, et al. Increased in Vivo Glial Activation in Patients with Amyotrophic Lateral Sclerosis: Assessed with [(11)C]-PBR28. NeuroImage Clinical. 2015;7:409-14. doi: 10.1016/j.nicl.2015.01.009.

21. Suridjan I, Pollock BG, Verhoeff NP, Voineskos AN, Chow T, Rusjan PM, et al. In-Vivo Imaging of Grey and White Matter Neuroinflammation in Alzheimer’s Disease: a Positron Emission Tomography Study with a Novel Radioligand, [18F]-FEPPA. Mol Psychiatry. 2015;20(12):1579-87. doi: 10.1038/mp.2015.1.

22. Kreisl WC, Lyoo CH, McGwier M, Snow J, Jenko KJ, Kimura N, et al. In Vivo Radioligand Binding to Translocator Protein Correlates with Severity of Alzheimer’s Disease. Brain: a Journal of Neurology. 2013;136(Pt 7):2228-38. doi: 10.1093/brain/awt145.

23. Datta G, Colasanti A, Kalk N, Owen D, Scott G, Rabiner EA, et al. (11)C-PBR28 and (18)F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine. 2017;58(9):1477-82. doi: 10.2967/jnumed.116.187161.

24. Da Pozzo E, Costa B, Martini C. Translocator Protein (TSPO) and Neurosteroids: Implications in Psychiatric Disorders. Current Molecular Medicine. 2012;12(4):426-42. doi: 10.2174/156652412800163451.

25. Rupprecht R, Rammes G, Eser D, Baghai TC, Schüle C, Nothdurfter C, et al. Translocator Protein (18 kD) as Target for Anxiolytics without Benzodiazepine-Like Side Effects. Science (New York, NY). 2009;325(5939):490-3. doi: 10.1126/science.1175055.

26. Costa B, Pini S, Martini C, Abelli M, Gabelloni P, Landi S, et al. Ala147Thr Substitution in Translocator Protein is Associated with Adult Separation Anxiety in Patients with Depression. Psychiatric Genetics. 2009;19(2):110-1. doi: 10.1097/YPG.0b013e32832080f6.

27. Owen DR, Fan J, Campioli E, Venugopal S, Midzak A, Daly E, et al. TSPO Mutations in Rats and a Human Polymorphism Impair the Rate of Steroid Synthesis. The Biochemical Journal. 2017;474(23):3985-99. doi: 10.1042/bcj20170648.

28. Prossin AR, Chandler M, Ryan KA, Saunders EF, Kamali M, Papadopoulos V, et al. Functional TSPO Polymorphism Predicts Variance in the Diurnal Cortisol Rhythm in Bipolar Disorder. Psychoneuroendocrinology. 2018;89:194-202. doi: 10.1016/j.psyneuen.2018.01.013.

29. Guo Y, Kalathur RC, Liu Q, Kloss B, Bruni R, Ginter C, et al. Protein Structure. Structure and Activity of Tryptophan-Rich TSPO Proteins. Science (New York, NY). 2015;347(6221):551-5. doi: 10.1126/science.aaa1534.

30. Batarseh A, Papadopoulos V. Regulation of Translocator Protein 18 kDa (TSPO) Expression in Health and Disease States. Molecular and Cellular Endocrinology. 2010;327(1-2):1-12. doi: 10.1016/j.mce.2010.06.013.

31. Hanisch UK, Kettenmann H. Microglia: Active Sensor and Versatile Effector Cells in The Normal and Pathologic Brain. Nature Neuroscience. 2007;10(11):1387-94. doi: 10.1038/nn1997.

32. Gao C, Jiang J, Tan Y, Chen S. Microglia in Neurodegenerative Diseases: Mechanism and Potential Therapeutic Targets. Signal Transduction and Targeted Therapy. 2023;8(1):359. doi: 10.1038/s41392-023-01588-0.

33. Monga S, Nagler R, Amara R, Weizman A, Gavish M. Inhibitory Effects of the Two Novel TSPO Ligands 2-Cl-MGV-1 and MGV-1 on LPS-induced Microglial Activation. Cells. 2019;8(5). doi: 10.3390/cells8050486.

34. Turnquist C, Harris BT, Harris CC. Radiation-Induced Brain Injury: Current Concepts and Therapeutic Strategies Targeting Neuroinflammation. Neuro-oncology Advances. 2020;2(1):vdaa057. doi: 10.1093/noajnl/vdaa057.

35. Hladik D, Tapio S. Effects of Ionizing Radiation on the Mammalian Brain. Mutation Research Reviews in Mutation Research. 2016;770(Pt B):219-30. doi: 10.1016/j.mrrev.2016.08.003.

36. Betlazar C, Middleton RJ, Howell N, Storer B, Davis E, Davies J, et al. Mitochondrial Translocator Protein (TSPO) Expression in the Brain after Whole Body Gamma Irradiation. Frontiers in Cell and Developmental Biology. 2021;9:715444. doi: 10.3389/fcell.2021.715444.

37. Родина АВ, Семочкина ЮП, Копаева МЮ, Стрепетов АН, Сафронов ВВ, Москалева ЕЮ. Состояние микроглии и когнитивные функции у мышей в отдаленный период после сочетанного действия низких доз гамма- и гамма-нейтронного излучения // Авиакосмическая и экологическая медицина. 2019. Т.53, №4. С. 65-73. [Rodina AV, Semochkina UP, Kopaeva MY, Strepetov AN, Safronov VV, Moskaleva EY. The State of Microglia and Cognitive Functions in Mice in the Long-Term Period after Combined Exposure to Low Doses of Gamma and Gamma Neutron Radiation. Aviakosmicheskaya i Ekologicheskaya Meditsina. 2019;53(4):65-73 (In Russ.)].

38. Rodina AV, Semochkina YP, Vysotskaya OV, Parfenova AA, Moskaleva EY. Radiation-induced Neuroinflammation Monitoring by the Level of Peripheral Blood Monocytes with High Expression of Translocator Protein. Int J Radiat Biol. 2023;99(9):1364-77. doi: 10.1080/09553002.2023.2177765.

39. Zhirnik AS SO, Semochkina JP, Shibaeva KD, Rodina AV, Ratushnjak MG,  Moskaleva EJ. Cognitive Impairment and Induction of Neuroinflammation in the Late Period after Single Whole Brain γ-Irradiation of Mice. Radiatsionnaya Biologiya Radioekologiya. 2021;61(1):32-43.

40.Nutma E, Stephenson JA, Gorter RP, de Bruin J, Boucherie DM, Donat CK, et al. A Quantitative Neuropathological Assessment of Translocator Protein Expression in Multiple Sclerosis. Brain: a Journal of Neurology. 2019;142(11):3440-55. doi: 10.1093/brain/awz287.

41. Gui Y, Marks JD, Das S, Hyman BT, Serrano-Pozo A. Characterization of the 18 kDa Translocator Protein (TSPO) Expression in Post-Mortem Normal and Alzheimer’s Disease Brains. Brain pathology (Zurich, Switzerland). 2020;30(1):151-64. doi: 10.1111/bpa.12763.

42. Kreisl WC, Kim MJ, Coughlin JM, Henter ID, Owen DR, Innis RB. PET Imaging of Neuroinflammation in Neurological Disorders. Lancet Neurol. 2020;19(11):940-50. doi: 10.1016/S1474-4422(20)30346-X.

43. Nettis MA, Veronese M, Nikkheslat N, Mariani N, Lombardo G, Sforzini L, et al. PET Imaging Shows No Changes in TSPO Brain Density after IFN-α Immune Challenge in Healthy Human Volunteers. Transl Psychiatry. 2020;10(1):89. doi: 10.1038/s41398-020-0768-z.

44. Dupont AC, Largeau B, Santiago Ribeiro MJ, Guilloteau D, Tronel C, Arlicot N. Translocator Protein-18 kDa (TSPO) Positron Emission Tomography (PET) Imaging and its Clinical Impact in Neurodegenerative Diseases. International Journal of Molecular Sciences. 2017;18(4). doi: 10.3390/ijms18040785.

45. Soustiel JF, Zaaroor M, Vlodavsky E, Veenman L, Weizman A, Gavish M. Neuroprotective Effect of Ro5-4864 Following Brain Injury. Experimental Neurology. 2008;214(2):201-8. doi: 10.1016/j.expneurol.2008.08.008.

46. Shiotani T, Nakamoto Y, Watabe S, Yoshii M, Nabeshima T. Anticonvulsant Actions of Nefiracetam on Epileptic EL Mice and Their Relation to Peripheral-Type Benzodiazepine Receptors. Brain Research. 2000;859(2):255-61. doi: 10.1016/s0006-8993(00)01971-5.

47. Parente A, de Vries EFJ, van Waarde A, Ioannou M, van Luijk P, Langendijk JA, et al. The Acute and Early Effects of Whole-Brain Irradiation on Glial Activation, Brain Metabolism, and Behavior: a Positron Emission Tomography Study. Molecular Imaging and Biology. 2020;22(4):1012-20. doi: 10.1007/s11307-020-01483-y.

48. Ma L, Zhang H, Liu N, Wang PQ, Guo WZ, Fu Q, et al. TSPO Ligand PK11195 Alleviates Neuroinflammation and Beta-Amyloid Generation Induced by Systemic LPS Administration. Brain Research Bulletin. 2016;121:192-200. doi: 10.1016/j.brainresbull.2016.02.001.

49. Scarf AM, Ittner LM, Kassiou M. The Translocator Protein (18 kDa): Central Nervous System Disease and Drug Design. Journal of Medicinal Chemistry. 2009;52(3):581-92. doi: 10.1021/jm8011678.

50. Ferzaz B, Brault E, Bourliaud G, Robert JP, Poughon G, Claustre Y, et al. SSR180575 (7-chloro-N,N,5-trimethyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide), a Peripheral Benzodiazepine Receptor Ligand, Promotes Neuronal Survival and Repair. The Journal of Pharmacology and Experimental Therapeutics. 2002;301(3):1067-78. doi: 10.1124/jpet.301.3.1067. 

51. Thominiaux C, Damont A, Kuhnast B, Demphel S, Le Helleix S, Boisnard S, et al. Radiosynthesis of 7-chloro-N,N-dimethyl-5-[11C]methyl-4-oxo-3-phenyl-3,5-dihydro-4H-pyridazino[4,5-b]indole-1-acetamide, [11C]SSR180575, a Novel Radioligand for Imaging the TSPO (peripheral benzodiazepine receptor) with PET. Journal of Labelled Compounds and Radiopharmaceuticals. 2010;53(13):767-73. doi: https://doi.org/10.1002/jlcr.1794.

52. Chauveau F, Boutin H, Van Camp N, Thominiaux C, Hantraye P, Rivron L, et al. In Vivo Imaging of Neuroinflammation in the Rodent Brain with [11C]SSR180575, a Novel Indoleacetamide Radioligand of the Translocator Protein (18 kDa). Eur J Nucl Med Mol Imaging. 2011;38(3):509-14. doi: 10.1007/s00259-010-1628-5.

53. Yasuno F, Ota M, Kosaka J, Ito H, Higuchi M, Doronbekov TK, et al. Increased Binding of Peripheral Benzodiazepine Receptor in Alzheimer’s Disease Measured by Positron Emission Tomography with [11C]DAA1106. Biological Psychiatry. 2008;64(10):835-41. doi: 10.1016/j.biopsych.2008.04.021.

54. Kim K, Kim H, Bae S-H, Lee S-Y, Kim Y-H, Na J, et al. CB251 PET/MR Imaging Probe Targeting Translocator Protein (TSPO) Independent of its Polymorphism in a Neuroinflammation Model. Theranostics. 2020;10(20):9315-31. doi: 10.7150/thno.46875.

55. Sutton JA, Clauss RP. A Review of the Evidence of Zolpidem Efficacy in Neurological Disability after Brain Damage Due to Stroke, Trauma and Hypoxia: a Justification of Further Clinical Trials. Brain Injury. 2017;31(8):1019-27. doi: 10.1080/02699052.2017.1300836.

56. Fan Z, Calsolaro V, Atkinson RA, Femminella GD, Waldman A, Buckley C, et al. Flutriciclamide (18F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein. Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine. 2016;57(11):1753-9. doi: 10.2967/jnumed.115.169078.

57. Scholz R, Caramoy A, Bhuckory MB, Rashid K, Chen M, Xu H, et al. Targeting Translocator Protein (18 kDa) (TSPO) Dampens Pro-Inflammatory Microglia Reactivity in the Retina and Protects from Degeneration. Journal of Neuroinflammation. 2015;12(1):201. doi: 10.1186/s12974-015-0422-5.

58. Li XB, Guo HL, Shi TY, Yang L, Wang M, Zhang K, et al. Neuroprotective Effects of a Novel Translocator Protein (18 kDa) Ligand, ZBD-2, against Focal Cerebral Ischemia and NMDA-Induced Neurotoxicity. Clinical and Experimental Pharmacology & Physiology. 2015;42(10):1068-74. doi: 10.1111/1440-1681.12460.

59. Stein DJ. Etifoxine Versus Alprazolam for the Treatment of Adjustment Disorder with Anxiety: a Randomized Controlled Trial. Advances in Therapy. 2015;32(1):57-68. doi: 10.1007/s12325-015-0176-6.

60. Barron AM, Garcia-Segura LM, Caruso D, Jayaraman A, Lee JW, Melcangi RC, et al. Ligand for Translocator Protein Reverses Pathology in a Mouse Model of Alzheimer’s Disease. J Neurosci. 2013;33(20):8891-7. doi: 10.1523/jneurosci.1350-13.2013.

61. Delage C, Vignal N, Guerin C, Taib T, Barboteau C, Mamma C, et al. From Positron Emission Tomography to Cell Analysis of the 18-kDa Translocator Protein in Mild Traumatic Brain Injury. Sci Rep. 2021;11(1):24009. doi: 10.1038/s41598-021-03416-3.

62. Kanegawa N, Collste K, Forsberg A, Schain M, Arakawa R, Jucaite A, et al. In Vivo Evidence of a Functional Association Between Immune Cells in Blood and Brain in Healthy Human Subjects. Brain Behav Immun. 2016;54:149-57. doi: 10.1016/j.bbi.2016.01.019.

63. Canat X, Carayon P, Bouaboula M, Cahard D, Shire D, Roque C, et al. Distribution Profile and Properties of Peripheral-Type Benzodiazepine Receptors on Human Hemopoietic Cells. Life Sci. 1993;52(1):107-18. doi: 10.1016/0024-3205(93)90293-c.

64. Sultana N, Sun C, Katsube T, Wang B. Biomarkers of Brain Damage Induced by Radiotherapy. Dose-response: a Publication of International Hormesis Society. 2020;18(3):1559325820938279. doi: 10.1177/1559325820938279.

65. Makale MT, McDonald CR, Hattangadi-Gluth JA, Kesari S. Mechanisms of Radiotherapy-Associated Cognitive Disability in Patients with Brain Tumours. Nat Rev Neurol. 2017;13(1):52-64. doi: 10.1038/nrneurol.2016.185.

66. Engler H, Brendt P, Wischermann J, Wegner A, Rohling R, Schoemberg T, et al. Selective Increase of Cerebrospinal Fluid IL-6 during Experimental Systemic Inflammation in Humans: Association with Depressive Symptoms. Mol Psychiatry. 2017;22(10):1448-54. doi: 10.1038/mp.2016.264.

 

 

 PDF (RUS) Full-text article (in Russian)

 

Conflict of interest. The author declare no conflict of interest.

Financing. The work was carried out within the state assigment of NRC «Kurchatov institute».

Contribution. The article was prepared with the sole participation of the author.

Article received: 20.01.2024. Accepted for publication: 27.02.2024.